Defibrotide
by Funmi Adewale| Brand Name: | |
| Generic Name: | defibrotide |
| Code Name: | |
| Company: | Gentium SpA |
| FDA Clinical Phase: | 1/2 |
Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may makes myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and only has a significant effect on myeloma when combined with cancer-fighting drugs. Defibrotide may decrease blood clotting and nerve damage caused by certain myeloma treatments. In combination with granulocyte colony-stimulating factor (G-CSF), defibrotide has been shown to significantly increase stem cell production. Defibrotide has also demonstrated an ability to treat hepatic veno-occulusive disease (VOD), a life-threatening complication of stem cell transplantation that is marked by blocked veins in the liver.
Clinical Trials:
There is currently one clinical trial studying defibrotide for the treatment of multiple myeloma, and participants are currently being recruited.
Web site for defibrotide: http://www.gentium.it/Defibrotide.aspx
Related Articles:
- Addition Of Defibrotide To Melphalan-Prednisone-Thalidomide Combination Produces Fewer Side Effects In Multiple Myeloma Patients
- Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
- New Recommendations Issued On Stem Cell Collection And Treatment With Revlimid, Thalidomide, And Velcade
- Autologous Stem Cell Transplant Therapy With Velcade-Revlimid Or Velcade-Thalomid in New Multiple Myeloma Patients (ASCO 2009)
- New Drug Enters Phase 2 Clinical Trial For Stem Cell Collection For Blood Cancer Patients
Leave a comment